Skip to product information
1 of 1

  • Images are for illustration purposes only
  • Gphc Registered
  • Join over 100k customers
  • Fixed prices and no subscriptions
  • Discreet next day delivery.
  • Free shipping on all orders over £50

Ralph Lauren Big Pony 1 Eau de Toilette 50ml Spray

Ralph Lauren Big Pony 1 Eau de Toilette 50ml Spray

  • 1. Ozempic®️-equivalent therapy now available for weight management
  • 2. Average weight loss of 17%, with 1 in 3 patients achieving over 20%
  • 3. May help reduce osteoarthritis-related pain
  • 4. Wegovy®️ is not expected to impact the effectiveness of oral contraceptives
  • 5. Supports cardiovascular risk reduction
  • 6. Over 22 million patients treated with semaglutide-based therapies since 2018

We’re proud to offer fast and discreet delivery for all our medicines & treatments.

Price Checker

Regular price £49.00
Sale price £49.00
Sale Sold out
  • Lowest price guarantee
  • Includes FREE private prescription
View full details

Ralph Lauren Big Pony 1 Eau de Toilette provides you with both confidence and style when you enter the game. The Big Pony Collection includes this vibrant invigorating fragrance which targets modern men who live life with passion and energy. The initial scent of Big Pony 1 starts with lime and citrus notes which create a sporty and fresh aroma suitable for daily use. The scent maintains a light profile while providing a crisp aroma that stays present without overwhelming the senses making it suitable for active people who enjoy spontaneous activities. The 50ml spray comes in a blue bottle featuring the green polo player logo which unites classic Ralph Lauren style with modern youthful appeal. Fragrance Notes: Top: Lime Heart: Citrus zest Base: Refreshing, sporty accord.

Key Features: Fresh, energizing scent profile Perfect for daytime and casual occasions Compact 50ml bottle – ideal for travel or gym bag Ralph Lauren Big Pony 1 creates a lasting impression through its fragrance which embodies the energetic spirit of youthful action and confident drive.

Patient Information Leaflet

Important - Before taking any medication, it is always important to read the Patient Information Leaflet (PIL)

Written and reviewed by our qualified team

GPhC Number: 2233073
Tarun Kumar

Reviewed by:

Tarun Kumar

Superintendent/ Clinical Lead

📖 Find out more about our team of medical content authors and how we ensure the accuracy of our content with our content guidelines.

Content last updated: 31 Mar 2025

We’re a safe and
regulated UK service

Registered Pharmacy Badge

Lowest Price Guarantee

We're convinced you won't find your treatment cheaper, but if you do we'll refund the difference.

Find out more

100% discreet packaging

We're convinced you won't find your treatment cheaper, but if you do we'll refund the difference.

Find out more

Agent

Need help?
Talk to our friendly experts now

How our service works

Service Setup

Service setup

Discreet Packaging

Discreet packaging

Express Delivery

Express delivery

Comparison of Weight Loss Injectables

Features

Mounjaro®

Injectable Pen

Wegovy®

Injectable Pen

Saxenda®

Injectable Pen

Active Ingredient Tirzepatide Semaglutide Liraglutide
Mechanism of Action GLP-1 and GIP receptor agonist GLP-1 receptor agonist GLP-1 receptor agonist
Administration Weekly injection Weekly injection Daily injection
Dosage Varies by patient, typically starting low Varies, typically starting at 0.25 mg Varies, starting at 0.6 mg
Effect on Appetite Significantly reduces appetite and cravings Reduces appetite and increases satiety Reduces appetite and increases satiety
Average Weight Loss Up to 20% body weight reduction Up to 15% body weight reduction Significant weight reduction
Side Effects Nausea, vomiting, diarrhoea, constipation Nausea, vomiting, diarrhoea, constipation Nausea, diarrhoea, constipation, hypoglycemia
Approval FDA-approved for weight loss FDA-approved for weight loss FDA-approved for weight loss
Suitable For Adults with BMI ≥30 or ≥27 with comorbidities Adults with BMI ≥30 or ≥27 with comorbidities Adults with BMI ≥30 or ≥27 with comorbidities